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Abstract
Unlike other antidepressants, mirtazapine does not in-
hibit the reuptake of norepinephrine or serotonin but
acts as an antagonist at presynaptic ·2-receptors, at post-
synaptic 5-HT2 and 5-HT3 receptors, and at histaminer-
gic H1 receptors. Furthermore, mirtazapine has been
shown to acutely inhibit cortisol secretion in healthy sub-
jects. In the present study, the impact of mirtazapine
treatment on salivary cortisol secretion was investigated
in 12 patients (4 men, 8 women) suffering from major
depression according to DSM-IV criteria. Patients were
treated with mirtazapine for 3 weeks, receiving 15 mg
mirtazapine on day 0, 30 mg on day 1 and 45 mg per day
from day 2 up to the end of the study (day 21). Response
to mirtazapine treatment was defined by a reduction of at
least 50% in the Hamilton Rating Scale for Depression
after 3 weeks of therapy. Salivary cortisol concentrations
were measured before treatment (day –1), at the begin-
ning of treatment (day 0), after 1 week (day 7) and after 3
weeks (day 21) of treatment with mirtazapine. Saliva
samples were collected hourly from 08.00 until 20.00 h.
The area under the curve values served as parameter for
the salivary cortisol secretion. Following analysis of vari-
ance with a repeated measures design, tests with con-
trasts revealed a significant reduction of cortisol concen-
trations already after 1 day of mirtazapine treatment that
was comparable in responders and nonresponders. In
addition to new pharmacological approaches such as
CRH1 receptor antagonists, mirtazapine therefore ap-
pears to be an effective strategy to decrease hypercorti-
solism and restore HPA system dysregulation in depres-
sion. However, the importance of the acute inhibitory
effects of mirtazapine on cortisol secretion for its antide-
pressant efficacy has to be further clarified.
Copyright © 2003 S. Karger AG, Basel
Introduction
The neuroendocrine challenge paradigm is based on
the involvement of monoamine pathways in the control of
anterior pituitary hormone secretion [1]. Psychotropic
drugs with different effects on the central neurotransmit-
ter system have distinct effects on the anterior pituitary
hormone secretion and can be characterized by certain
pharmacoendocrinological profiles (table 1). Antidepres-
sants which primarily act via noradrenaline (NA) reup-
take inhibition (e.g. desimipramine, DMI) stimulate
growth hormone (GH) secretion [23], whereas serotonin
(5-HT) reuptake-inhibiting antidepressants (e.g. indal-
pine, chlorimipramine) are characterized by prolactin
(PRL) stimulation [4]. Cortisol (COR) secretion can
acutely be increased by antidepressants with both NA or
5-HT reuptake inhibition; the stimulatory effects of anti-
depressants on COR secretion are mediated via stimula-
tion of the ACTH output of the pituitary gland [4].
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Table 1. The influence of acute
administration of antidepressant agents on
neurotransmitter reuptake in vitro
(IC50 values) and GH, PRL and COR
secretion in man
NA 5-HT DA GH PRL COR
0.9 210 V DMI 25 mg i.v. +++ ++ +++
DMI 100 mg p.o. +++ + +++
1.1 V V D-Oxa 75 mg i.v. +++ 0 +++
V V V L-Oxa 75 mg p.o. 0 0 0
6.6 830 48 NF 200 mg p.o. ++ – n.a.
24 1.5 V CI 25 mg i.v. ++ +++ +++
CI 100 mg p.o. ++ + +
V 2.4 V IND 25 mg i.v. 0 ++ +++
V = IC50 11,000 nM; NA = noradrenaline; 5-HT = serotonin; DA = dopamine; DMI =
desipramine; Oxa = oxaprotiline; NF = nomifensine; CI = chlorimipramine; IND = in-
dalpine; i.v. = intravenous; n.a. = not available; p.o. = per os; +++ = strong stimulation;
++ = moderate stimulation; + = slight stimulation; – = inhibition; 0 = no significant effect.
Table modified from Hyttel [2].
Unlike other antidepressants, mirtazapine does not
inhibit the reuptake of norepinephrine or serotonin but
acts as an antagonist at presynaptic ·2-receptors and at
postsynaptic 5-HT2 and 5-HT3 receptors [5]. Mirtaza-
pine enhances NA release by blocking ·2-autoreceptors [5,
6]. Serotonergic neurotransmission is also increased by
mirtazapine, especially in the hippocampus, via two syn-
ergistic mechanisms: an increase of 5-HT cell firing and a
blockade of ·2-adrenergic heteroreceptors at the 5-HT
nerve terminals [7–9]. In addition, mirtazapine is an anti-
histaminergic agent with a high affinity for histamine H1
receptors [10] and has only few anticholinergic side
effects. Average peak plasma concentrations are achieved
2 h after oral dosing and the elimination half-life is in the
range of 20–40 h [11].
In former studies of our research group mirtazapine
was shown to acutely inhibit COR and ACTH secretion in
healthy subjects, whereas GH and PRL secretion patterns
remained unchanged [12, 13]. The endocrinological ef-
fects of mirtazapine observed in healthy volunteers
strongly differ from those seen in reuptake-inhibiting
antidepressants and may reflect the unique mechanism of
action of mirtazapine. Whereas reuptake inhibitors acute-
ly stimulate the COR release of the adrenal gland in
healthy volunteers [4, 14–16], mirtazapine obviously acts
as an acute cortisol inhibitor in normal controls.
The COR inhibition after first-time administration of
mirtazapine in normal volunteers is of special interest in
the light of the hypercortisolism demonstrated in depres-
sive patients. Preclinical and clinical studies suggest that
hypothalamic-pituitary-adrenal (HPA) system dysregula-
tion is related to the occurrence of depression [17]. Signif-
icantly elevated urinary free COR excretion or 24-hour
COR blood concentrations have been shown in severely
depressed patients [18–23]. Furthermore, COR escape
from dexamethasone suppression has been reported dur-
ing major depression [24–27]. If the combined dexameth-
asone suppression/CRH stimulation test (DEX/CRH
test) is used, the sensitivity in discriminating between
depressive patients and healthy controls can be further
increased [28]. These findings give reason to ask whether
mirtazapine is able to rapidly restore HPA axis dysregula-
tion in depressive disorder by acute reduction of COR
secretion patterns.
Methods
Subjects
The study was carried out according to the fifth revision of the
Declaration of Helsinki [29] and had been approved by an ethics
committee. Twelve depressive inpatients (4 men, 8 women) gave
informed written consent and were included in this study. Inclusion
criteria were (a) a major depressive episode according to DSM-IV
criteria [30]; (b) a score of at least 18 on the 21-item Hamilton
Depression Rating Scale (21-HAMD [31]); (c) no history of sub-
stance abuse or dependency; (d) exclusion of neurological or medical
disorders, and (e) no psychotropic drugs for at least 5 days prior to
the study, except chloralhydrate given in case of patients experienc-
ing difficulties sleeping. Any physical illness was ruled out by a thor-
ough physical and psychiatric examination and routine laboratory
test, including electrocardiogram and electroencephalogram. None
of the female patients received hormonal contraceptives or hormone
replacement therapy. Clinical characteristics are given in table 2.
Mirtazapine Treatment, Collection of Saliva Samples and
Clinical Ratings
The 12 patients were treated with mirtazapine monotherapy for
at least 3 weeks. They received 15 mg mirtazapine at 08.00 h on day
0; 30 mg on day 1 (15 mg at 08.00 h, 15 mg at 22.00 h), and 45 mg/
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Table 2. Demographic and clinical data of
12 depressed patients treated with
mirtazapine
Patient Sex/age,
years
DSM-IV
diagnosis
21-HAMD
day –1 day 0 day 7 day 21
Response
1 M/25 296.23 28 26 10 5 R
2 F/60 296.24 36 36 33 32 NR
3 F/30 296.33 35 32 22 14 R
4 F/41 296.32 26 27 25 16 NR
5 F/48 296.32 23 23 13 9 R
6 F/34 296.32 29 28 24 19 NR
7 F/28 296.23 33 29 23 19 NR
8 F/21 296.33 28 27 25 27 NR
9 M/40 296.32 19 14 7 5 R
10 M/51 296.32 22 18 10 10 R
11 M/45 296.32 22 22 10 16 NR
12 F/56 296.32 20 18 12 10 R
21-HAMD: Hamilton Depression Rating Scale, 21-items, sum score; day –1: before mir-
tazapine treatment; day 0: first application of 15 mg mirtazapine; day 7 and day 21: continu-
ation of mirtazapine treatment at a dosage of 45 mg/day; Response = 650% reduction in
21-HAMD sum score after 21 days of mirtazapine treatment; R = responder; NR = nonre-
sponder.
day (15 mg at 08.00 h, 30 mg at 22.00 h) from day 2 up to the end of
the study (day 21). Salivary COR concentrations were measured
before treatment (day –1), at the beginning of treatment (day 0), after
1 week (day 7) and after 3 weeks (day 21) of treatment with mirtaza-
pine. On each study day (–1, 0, 7, 21) saliva samples were collected
hourly from 08.00 h up to 20.00 h. Severity of depression was
assessed on the days of saliva sampling using the 21-HAMD.
Response to mirtazapine treatment was defined by a reduction of at
least 50% in the 21-HAMD sum score after 3 weeks of therapy. All
raters were experienced psychiatrists and blind to hormonal mea-
surements.
Measurement of Salivary COR
Saliva was obtained using special tubes containing a small cotton
wool swab (Salivette, Sarstedt, Rommelsdorf, Germany). Patients
were asked to take the tube, open it and put the cotton swab into the
mouth. After 3 min patients had to take the swab out and put it back
into the tube.
A special radioimmunoassay (‘Magic COR’, Ciba Corning, Fern-
wald, Germany) was used to determine COR concentrations in the
salivary samples. As previously described by Kirschbaum et al. [32],
this assay was slightly modified using diluted standards (1:10), a pro-
longed time of incubation (3.5 h), and a different amount of tracer as
well as antibody to obtain a concentration range typical for saliva
COR, which (representing the free fraction of the hormone) is about
1:10 lower in saliva than in peripheral blood.
Statistical Evaluation
The area under the curve (AUC) values between t = 0 h and t = 12
h served as parameter for the salivary COR secretion. Correlations
between baseline AUC values (day –1) and both age and severity of
illness at baseline (as measured by the 21-HAMD sum score at day
–1) were tested for significance using Pearson’s correlation coeffi-
cient. To compare the salivary COR secretion before and during mir-
tazapine treatment (day –1, 0, 7, and 21) and to compare the change
in salivary COR levels during mirtazapine therapy between respond-
ers and nonresponders, a two-way ANOVA with a repeated measures
design was carried out. ‘Treatment’, i.e. the salivary COR AUC val-
ues before and during mirtazapine treatment (day –1, 0, 7, and 21),
was the within-subjects factor, whereas ‘group’ served as between-
subjects factor (response versus nonresponse). As a follow-up proce-
dure to make pairwise comparisons between the AUC values during
mirtazapine treatment (day 0, 7, 21) and the baseline AUC values
(day –1), respectively, tests with contrasts were performed. As a nom-
inal level of significance, · = 0.05 was accepted.
Results
Six patients responded to 3-week mirtazapine treat-
ment, whereas the other 6 patients were nonresponders.
At baseline (week 0), the 21-HAMD sum scores were
comparable between responders and nonresponders (t =
1.410; d.f. = 10; p = n.s.). During mirtazapine treatment,
responders showed a clear-cut amelioration of depressive
symptoms, whereas nonresponders remained depressed.
Mean 21-HAMD sum scores were (mean B SD): re-
sponders day –1: 24.50 B 6.02; day 0: 21.83 B 6.52; day
7: 12.33 B 5.16; day 21: 8.83 B 3.43; nonresponders day
–1: 29.00 B 4.98; day 0: 28.17 B 4.54; day 7: 23.33 B
7.45; day 21: 21.50 B 6.53. Male and female patients
were comparable in baseline COR AUC values (t = 1.175;
d.f. = 10; p = n.s.). However, there was a significant posi-
tive correlation between age and salivary COR AUC val-
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Fig. 1. Means B SEM of salivary COR AUC values in depressed
patients (n = 12) on day –1 (before mirtazapine treatment), day 0
(first application of 15 mg mirtazapine), day 7 and day 21 (continua-
tion of mirtazapine treatment at a dosage of 45 mg/day). * p ! 0.05;
** p ! 0.01. For further statistics please see Results.
Fig. 2. Means B SEM of salivary COR concentrations in depressed
patients (n = 12) on day –1 (before mirtazapine treatment), day 0
(first application of 15 mg mirtazapine), day 7 and day 21 (continua-
tion of mirtazapine treatment at a dosage of 45 mg/day). Mean value
graph represents the salivary COR concentrations from 08.00 (t =
0 h) to 20.00 h (t = 12 h).
ues on day –1 (r = 0.693; p = 0.013). Thus ‘age’ was con-
sidered a covariate in the repeated measures ANOVA in
order to eliminate its influence on the possible effects of
the factors ‘treatment’ and ‘group’.
Before mirtazapine treatment, the mean salivary COR
AUC value was 85.78 B 37.16 nmol/l ! hour. However,
there was a pronounced reduction of COR AUC values
after the first administration of mirtazapine (day 0) al-
ready, which lasted up to the end of the treatment period
(day 0: 66.77 B 30.24, day 7: 68.10 B 22.99, day 21:
53.95 B 14.79 nmol/l ! hour; fig. 1, 2). Repeated mea-
sures ANOVA (Wilks’ multivariate tests of significance)
revealed a significant ‘treatment’ effect (F = 4.721; d.f. =
3, 7; sign. of F = 0.042), suggesting an significant inhibito-
ry impact of mirtazapine on cortisol secretion. However,
there was no significant ‘group’ effect (responders vs. non-
responders: F = 0.090; d.f. = 1, 9; sign. of F = 0.771) nor
was there any significant ‘treatment by group’ effect (F =
0.377; d.f. = 3, 7; p = 0.773). In other words, the decline in
cortisol secretion patterns (salivary COR AUC values)
due to mirtazapine therapy was comparable between
responders and nonresponders. In the post-hoc tests with
contrasts, there was a significant decrease of COR AUC
values already after the first day of mirtazapine treatment
(p = 0.05). COR inhibition became also obvious on day 7;
however, compared to baseline (day –1) the difference
was not statistically significant (p = 0.07). On day 21, a
highly significant reduction of COR secretion in compari-
son to day –1 could be demonstrated (p = 0.001).
Discussion
We found a positive correlation between age and COR
secretion (salivary COR AUC values) at baseline (day –1).
This result is in line with investigators who have found
age to be positively associated with COR secretion during
depression [33, 34], especially in women [35] and severely
depressed patients [36].
The main finding of our investigation is that mirtaza-
pine significantly decreases COR secretion in depressive
patients. Apparently, this COR inhibition is acute and
begins after the first administration of mirtazapine, since
on day 0 (application of 15 mg mirtazapine at 08.00 h) the
mean COR concentrations were already reduced 1 h after
administration of mirtazapine compared to the drug-free
condition (fig. 2). During the following 3 weeks of mirta-
zapine treatment, diurnal COR secretion was further
reduced by mirtazapine, reaching a minimum after 3
weeks of therapy. The decline of salivary COR concentra-
tions from morning to evening, already observed before
mirtazapine treatment (day –1), can be explained best by
the circadian rhythm of COR secretion (maximum of
COR concentrations early in the morning followed by a
physiological reduction of COR levels).
The acute COR inhibition by mirtazapine, which can
be demonstrated both in healthy subjects [12, 13] and
depressed patients [the present study], can hardly be
explained by the ·2-blocking properties of mirtazapine
because yohimbine, an ·2-blocker, increases the DMI-
induced COR stimulation in humans [14]. Given alone,
1
2
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COR release from the adrenal gland is not influenced by
yohimbine [37]. However, there is evidence from the liter-
ature that antagonism of central 5-HT2 and histamine H1
receptors may be responsible for the acute inhibitory
effects of mirtazapine on COR secretion.
Different reports have demonstrated that both the syn-
thesis and release of CRH by hypothalamic tissues in
vitro [38, 39] and in vivo [40–42] are stimulated by 5-HT,
and that the antiserotonergic drug cyproheptadine inhib-
its these effects [39]. It seems that 5-HT is one of the phys-
iological factors involved in CRH stimulation at the hypo-
thalamic level [43]. The inhibitory effect of cyprohepta-
dine on ACTH secretion via CRH is thought to be respon-
sible for the positive results observed in some patients
with Cushing disease treated with cyproheptadine [44,
45]. Furthermore, it has been shown that activation of 5-
HT1A, 5-HT2A and 5-HT2C, but not of 5-HT3 receptors
results in elevated levels of plasma corticosterone; accord-
ing to Berendsen et al. [46], serotonergic modulation of
ACTH release via CRH plays an important role in this
context. In the face of the presumed serotonergic modula-
tion of CRH, ACTH and COR secretion, it seems to be
likely that the COR inhibition seen after application of
mirtazapine is, at least in parts, caused by its 5-HT2A and
5-HT2C receptor-blocking properties.
Besides serotonergic transmission, the neurotransmit-
ter histamine also has to be taken into account. Histamine
stimulates the release of ACTH via activation of central
postsynaptic H1 or H2 receptors; the effect of histamine is
indirect and may involve the hypothalamic-regulating
factors CRH and arginine vasopressin [47]. In normal
human volunteers, the selective H1 receptor antagonist
meclastine is able to inhibit the ACTH and COR stimula-
tion in the insulin hypoglycemia test, whereas GH and
PRL concentrations are unaffected [48]. In rats, antide-
pressants which display an H1 antihistaminergic activity
(such as imipramine, doxepin, mianserin, desipramine,
and amitriptyline) significantly suppress the histamine-
induced ACTH release [49]. Regarding these human and
animal studies, the H1-blocking effects of mirtazapine
may also play a role in the COR inhibition demonstrated
in our investigation.
There is evidence that antidepressants with reuptake-
inhibiting properties may act in part through gradual nor-
malization of HPA system hyperactivity [17, 50]. Fur-
thermore, in patients who respond clinically to antide-
pressant therapy but still have a substantially increased
COR response in the combined DEX/CRH test at dis-
charge, a higher risk for relapse within the following 6
months has been demonstrated [51]. In contrast to mirta-
zapine, reuptake-inhibiting antidepressants acutely stim-
ulate COR and ACTH secretion [4, 14–16] and may nor-
malize HPA axis hyperactivity in depressed patients via
upregulation of glucocorticoid receptor mRNA levels and
enhancement of glucocorticoid receptor function [52].
Apparently, the acute COR inhibition in healthy subjects
and depressed patients after administration of mirtaza-
pine is due to a direct pharmacoendocrinological effect of
this antidepressant (presumably acute reduction of hypo-
thalamic CRH release by blockade of central 5-HT2 and/
or H1 receptors), which seems to be different from the
gradual normalization of COR and ACTH hypersecretion
observed during treatment with reuptake inhibitors such
as amitriptyline [50].
Future studies will have to investigate the long-term
effects of mirtazapine on COR secretion and its influence
on HPA axis activity in depressed patients as measured
by the combined DEX/CRH test. Since the COR inhibi-
tion was comparable in responders and nonresponders,
the importance of the acute inhibitory effects of mirtaza-
pine on COR secretion for its antidepressant efficacy has
to be further clarified. In addition to new pharmacological
approaches such as CRH1 receptor antagonists [17], mir-
tazapine may be an effective strategy to restore HPA sys-
tem dysregulation in depression.
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